摘要
细胞色素P450第2家族W亚族的多肽1(CYP2W1)是一种新发现的单加氧酶,特别是在肿瘤组织和胎儿期有表达。尤其是在60%大肠癌被观察到有高表达,其表达与预后差有关。CYP2W1已经显示多种代谢内源性底物包括溶血磷脂和几个致癌物,如多环芳香烃。然而,特定的CYP2W1底物目前未能得知。由于其肿瘤特异性表达及其在大肠癌中独特的的催化活性,CYP2W1被视为在大肠癌治疗中的令人关注的靶点。本综述旨在总结目前对CYP2W1生物学和生物化学上的认识,包括基因的多态性和癌症的风险性,以及与肿瘤特异性诊断和治疗靶点的相关性。
关键词: 癌症治疗,大肠癌,细胞色素P450第2家族W亚族的第1多肽(CYP2W1),细胞色素P450,前体药物
图形摘要
Current Cancer Drug Targets
Title:Cytochrome P450 2W1 (CYP2W1) in Colorectal Cancers
Volume: 16 Issue: 1
Author(s): Felicia Fei-Lei Chung, Chun Wai Mai, Pei Yuen Ng and Chee-Onn Leong
Affiliation:
关键词: 癌症治疗,大肠癌,细胞色素P450第2家族W亚族的第1多肽(CYP2W1),细胞色素P450,前体药物
摘要: Cytochrome P450, family 2, subfamily W, polypeptide 1 (CYP2W1) is a newly identified monooxygenase enzyme that is expressed specifically in tumor tissues and during fetal life. Particularly, high expression of CYP2W1 was observed in up to 60% of colorectal cancers and its expression correlated with poor survival. CYP2W1 has been shown to metabolize various endogenous substrates including lysophospholipids and several procarcinogens, such as polycyclic aromatic hydrocarbon. The specific substrate for CYP2W1, however, is currently unknown. Due to its tumor-specific expression and its unique catalytic activities in colorectal cancers, CYP2W1 was deemed as an interesting target in colorectal cancer therapy. This review sought to summarize the current understanding of the CYP2W1 biology and biochemistry, its genetic polymorphisms and cancer risk, and its implication as a tumor-specific diagnostic and therapeutic target.
Export Options
About this article
Cite this article as:
Felicia Fei-Lei Chung, Chun Wai Mai, Pei Yuen Ng and Chee-Onn Leong , Cytochrome P450 2W1 (CYP2W1) in Colorectal Cancers, Current Cancer Drug Targets 2016; 16 (1) . https://dx.doi.org/10.2174/1568009616888151112095948
DOI https://dx.doi.org/10.2174/1568009616888151112095948 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Tubulin Inhibitors: A Patent Survey
Recent Patents on Anti-Cancer Drug Discovery Mitochondrial Toxicity in HAART: An Overview of In Vitro Evidence
Current Pharmaceutical Design MicroRNA-203: Tumor Suppression and Beyond
MicroRNA Diastereoselective Addition of Organometallic Reagents to Diimines Derived from (R,R)-1,2-Diaminocyclohexane and Aromatic Aldehydes
Letters in Organic Chemistry Review of Bioinformatics and QSAR Studies of β-Secretase Inhibitors
Current Bioinformatics Biomarkers for Early Detection of Colitis-associated Colorectal Cancer - Current Concepts, Future Trends
Current Drug Targets Microsomal Prostaglandin E Synthase: A Key Enzyme in PGE2 Biosynthesis and Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents BUB1B Promotes Proliferation of Prostate Cancer via Transcriptional Regulation of MELK
Anti-Cancer Agents in Medicinal Chemistry Current Advances in the Development of Anticancer Drugs Targeting Tyrosine Kinases of the Src Family
Current Drug Therapy Can We Select Patients for Colorectal Cancer Prevention with Aspirin?
Current Pharmaceutical Design Fluoropyrimidine-associated Toxicities in Colorectal Cancer Patients: The Epigenetic Point of View
Clinical Cancer Drugs miR-21, An Oncogenic Target miRNA for Cancer Therapy: Molecular Mechanisms and Recent Advancements in Chemo and Radio-resistance
Current Gene Therapy Phytometabolites Targeting the Warburg Effect in Cancer Cells: A Mechanistic Review
Current Drug Targets The Hydroxamic Acids as Potential Anticancer and Neuroprotective Agents
Current Medicinal Chemistry Olive Oil and Cancer Risk: an Update of Epidemiological Findings through 2010
Current Pharmaceutical Design Clinical Pharmacogenetics in Oncology: the Paradigm of Molecular Targeted Therapies
Current Pharmaceutical Design Micronutrients at the Interface Between Inflammation and Infection Ascorbic Acid and Calciferol. Part 2: Calciferol and the Significance of Nutrient Supplements
Inflammation & Allergy - Drug Targets (Discontinued) Potential Therapeutic Targets of Curcumin, Most Abundant Active Compound of Turmeric Spice: Role in the Management of Various Types of Cancer
Recent Patents on Anti-Cancer Drug Discovery Expression and Function of Organic Cation and Anion Transporters (SLC22 Family) in the CNS
Current Pharmaceutical Design Anti-angiogenic Treatment in Metastatic Colorectal Cancer: Current Issues and Future Aims
Current Cancer Therapy Reviews